LACTOLOGY FOUNDATION

Enzyme and Acid Preparations, Combinations (ATC A09AC): Toxicological and Lactological Monograph

ATC code: A09AC
ATC designation: Enzyme and acid preparations, combinations
Higher ATC group: A09A — Digestives, including enzymes
Therapeutic category: Digestive preparations combining enzymatic and acidifying components
Principal subclasses: A09AC01 — pepsin and acid preparations; A09AC02 — multienzymes and acid preparations

ATC class and general pharmacology

A09AC comprises enzyme and acid preparations used in combination and is classified within A09A, the ATC group encompassing digestives, including enzymes. The class represents combination therapy in which digestive enzymatic activity is supplemented by an acidifying component. The current WHO ATC/DDD classification divides A09AC into A09AC01 (pepsin and acid preparations) and A09AC02 (multienzymes and acid preparations).

The pharmacological rationale of the class is predominantly local gastrointestinal digestive support rather than systemic pharmacological action.

The enzyme component is intended to facilitate hydrolysis of dietary macromolecules. Depending on the formulation, enzymatic activity may be directed toward proteins or may encompass several nutrient classes through combinations of proteolytic, lipolytic, and/or amylolytic activities. The acidifying component is intended to establish or reinforce an intragastric environment favorable to digestion and, in appropriate formulations, to acid-dependent enzymatic activity.

This complementary mechanism distinguishes A09AC preparations from enzyme-only preparations and acid preparations administered separately. The therapeutic concept combines enhancement of digestive substrate breakdown with modification of the physicochemical environment in which digestion occurs.

The pharmacology of the class is therefore principally intraluminal. Digestive enzymes are generally large protein molecules whose intended action occurs within the gastrointestinal tract. They catalyze substrate-specific hydrolytic reactions and are subsequently themselves susceptible to proteolytic degradation into smaller peptides and amino acids. The acid component acts predominantly through alteration of luminal pH and is subsequently buffered, neutralized, dissociated, metabolized, or incorporated into normal physiological electrolyte and acid-base pathways according to its chemical identity.

As a consequence, conventional pharmacokinetic concepts such as systemic bioavailability, plasma protein binding, volume of distribution, hepatic clearance, and plasma elimination half-life are often of limited relevance to the principal therapeutic action of the class.

The clinical pharmacology of individual A09AC products nevertheless cannot be regarded as completely uniform. Formulations may differ substantially in enzyme composition and activity, acidifying component, dosage form, concentration, excipients, pharmaceutical protection of enzyme activity, and intended site of action. These differences are particularly important when evaluating an individual medicinal product.

At class level, the major pharmacodynamic characteristics can be summarized as follows:

Because enzyme content and potency can vary substantially between digestive-enzyme products, dose equivalence should not be assumed across preparations. Individual formulations must be assessed according to their specific composition and declared enzymatic activity.

Toxicological profile

The toxicological profile of A09AC preparations reflects their combined composition. At class level, toxicity can be divided conceptually into effects associated with the digestive enzyme component, effects associated with acidifying substances, and effects attributable to formulation-specific ingredients.

Under appropriate therapeutic conditions, the principal toxicological concerns are predominantly local gastrointestinal intolerance, mucosal irritation, hypersensitivity, and consequences of inappropriate concentration or excessive exposure rather than classical systemic organ toxicity.

Gastrointestinal toxicity

The gastrointestinal tract is both the therapeutic target and the principal site at which adverse effects may occur.

Potential reactions include nausea, epigastric discomfort, abdominal pain, altered bowel habits, diarrhea, constipation, or other nonspecific gastrointestinal symptoms. Their occurrence and severity depend on the formulation, enzymatic activity, acid concentration, administered dose, underlying gastrointestinal pathology, and individual susceptibility.

Acidifying components may aggravate pre-existing acid-related gastrointestinal symptoms in susceptible patients. Excessively concentrated acidic preparations may produce direct mucosal irritation and, depending on the acid involved and the magnitude of exposure, potentially more significant chemical injury.

This risk should be distinguished from the controlled acidification produced by correctly formulated medicinal products at therapeutic doses.

Local irritant and corrosive potential

The local toxicity of the acid component is strongly concentration dependent.

Appropriately formulated oral medicinal products are designed to limit uncontrolled tissue exposure. In contrast, accidental exposure to concentrated acidic substances used as pharmaceutical ingredients can cause irritation or corrosive injury to the oral cavity, esophagus, stomach, eyes, skin, or respiratory tract.

Consequently, toxicological conclusions derived from concentrated chemical exposure should not be extrapolated directly to finished medicinal products containing appropriately diluted or formulated acidifying agents.

Enzyme-related toxicity

Digestive enzymes generally exert their intended action locally and are proteins or protein-derived substances. Their toxicological profile therefore differs from that of conventional low-molecular-weight systemically active drugs.

The principal class-related concern is hypersensitivity. Enzymatic preparations, particularly those derived from animal, microbial, fungal, or other biological sources, may act as allergens in susceptible individuals.

Allergic manifestations can theoretically range from localized reactions to systemic hypersensitivity. Occupational exposure to enzyme powders or aerosols may carry a different sensitization profile from oral therapeutic exposure and should not be considered pharmacologically equivalent.

Proteolytic activity may also contribute to local irritation if active enzymes contact susceptible mucosal tissues at inappropriate concentrations or outside their intended physiological environment.

Systemic toxicity

Clinically important systemic toxicity is not expected to be a dominant characteristic of correctly used A09AC preparations because the therapeutic action is primarily intraluminal and systemic absorption of intact digestive enzymes is expected to be very limited.

The acidifying component may enter physiological metabolic or electrolyte pathways after neutralization or absorption, depending on its identity. At ordinary therapeutic doses, this does not necessarily translate into meaningful systemic toxicity.

However, extreme exposure, severe renal or metabolic disease, electrolyte disturbances, or unusual formulation characteristics may alter the risk profile. The toxicological assessment of an individual product must therefore account for the chemical identity and quantity of its acid component rather than treating all A09AC preparations as interchangeable.

Overdose

There is no single toxic syndrome applicable to the entire A09AC class.

Excessive administration may intensify gastrointestinal adverse effects and local irritation. The consequences of substantial overdose are likely to depend more strongly on the specific acidifying agent, enzyme composition, concentration, excipients, and total amount ingested than on the ATC classification itself.

Severe symptoms after accidental ingestion of a concentrated or incorrectly prepared product warrant medical and toxicological evaluation.

Long-term toxicity

No unified chronic systemic toxicity profile can be assigned to A09AC as a whole because the class contains heterogeneous combination preparations.

With conventional therapeutic administration, chronic toxicity is expected to be determined primarily by individual ingredients, dose, formulation, and duration of exposure. Persistent exposure of dental surfaces to strongly acidic oral formulations may theoretically contribute to enamel erosion, whereas repeated exposure to biologically derived enzymes may be relevant to sensitization in predisposed individuals.

Carcinogenicity, genotoxicity, reproductive toxicity, and organ-specific chronic toxicity should therefore be assessed at the individual ingredient or medicinal-product level rather than extrapolated from the A09AC classification itself.

General toxicological assessment

Lactation pharmacology and infant exposure

Direct lactation data for A09AC combination preparations are limited. Consequently, the lactological assessment of the class relies substantially on mechanistic pharmacology, the predominantly gastrointestinal site of action, physicochemical properties of digestive enzymes, physiological handling of acidifying components, and the characteristics of individual formulations.

Maternal systemic exposure

The most important pharmacokinetic consideration is that the intended therapeutic effects of A09AC preparations occur primarily within the maternal gastrointestinal lumen.

Digestive enzymes are generally high-molecular-weight proteins. Their absorption as pharmacologically active intact molecules from the adult gastrointestinal tract is expected to be very limited. They are instead susceptible to digestion and degradation into peptides and amino acids.

Accordingly, clinically meaningful concentrations of intact digestive enzymes in maternal plasma — and therefore subsequent transfer of active intact enzymes into breast milk — are not generally expected after conventional oral use.

The acid component requires a somewhat different assessment. Acidifying agents undergo dissociation, neutralization, buffering, or normal metabolic processing according to their chemical structure. Their constituents may enter endogenous physiological pools, but this is not equivalent to transfer of an intact medicinal acid preparation into human milk.

Thus, for both major components of the class, pharmacologically important infant exposure through breast milk is mechanistically expected to be limited during ordinary maternal treatment.

Transfer into human milk

Specific milk-to-plasma ratios have not been established for the A09AC class as a whole and would have limited interpretive value because the class contains heterogeneous combination products.

Similarly, a single relative infant dose (RID) cannot be assigned to A09AC.

For digestive enzymes, calculation of a conventional RID may be biologically inappropriate when systemic absorption of pharmacologically active intact enzyme is negligible.

For acidifying substances, assessment depends on the specific compound. Some components or their ions may already be normal constituents of maternal plasma and human milk, while others undergo rapid neutralization or metabolism before meaningful mammary transfer could occur.

Consequently, the absence of a numerical RID should not automatically be interpreted as evidence of high lactational risk. It principally reflects the nature of these substances and the scarcity of direct milk pharmacokinetic studies.

Exposure and gastrointestinal handling by the infant

Even if trace quantities of enzyme-derived protein material were present in human milk, orally ingested proteins would ordinarily encounter the infant's gastrointestinal digestive environment. This provides an additional biological barrier to systemic exposure to intact enzymatically active molecules.

Nevertheless, neonatal gastrointestinal physiology differs from that of adults, particularly in premature or medically fragile infants. Therefore, theoretical assumptions regarding protein degradation should not replace clinical judgment when maternal treatment involves unusual doses, nonstandard preparations, or products containing additional pharmacologically active ingredients.

The acidifying component is likewise unlikely to produce clinically significant acid exposure through breast milk following normal maternal administration. Maternal acid-base regulation and mammary homeostasis substantially limit the relevance of direct extrapolation from the acidity of the swallowed maternal preparation to the composition of breast milk.

Potential adverse effects in the breastfed infant

No characteristic neonatal toxicity syndrome can be attributed to the A09AC class on the basis of current pharmacological principles.

Potential theoretical concerns would include gastrointestinal intolerance or hypersensitivity, particularly when a preparation contains biologically derived proteins capable of allergenic reactions. However, the likelihood and clinical significance of such effects depend on the individual formulation, maternal systemic exposure, and infant susceptibility.

Special attention may be appropriate in premature neonates, infants with severe gastrointestinal disease, infants with known food or protein hypersensitivity, and situations involving unusually high maternal exposure.

Effects on lactation

There is no established class mechanism by which locally acting digestive enzyme–acid combinations would be expected to inhibit prolactin secretion, interfere with oxytocin-mediated milk ejection, or directly suppress mammary milk production.

Clinically relevant adverse effects on lactogenesis or established milk supply are therefore not expected as a general pharmacological property of A09AC preparations.

Nevertheless, substantial maternal gastrointestinal adverse effects — for example persistent vomiting, diarrhea, reduced nutritional intake, or dehydration — could indirectly impair maternal wellbeing and potentially affect breastfeeding. Such effects would represent consequences of maternal illness or intolerance rather than a direct pharmacological inhibition of lactation.

Lactological safety assessment and clinical recommendations

At class level, oral A09AC enzyme and acid combination preparations are expected to present a generally low risk to the breastfed infant when used appropriately at therapeutic doses.

This assessment is based predominantly on pharmacological plausibility rather than extensive direct clinical lactation studies. The principal supporting considerations are the local gastrointestinal action of the preparations, limited systemic availability of intact digestive enzymes, physiological degradation of protein enzymes, and buffering or metabolic handling of acidifying components.

Routine interruption of breastfeeding would therefore not generally be expected solely because a mother is receiving an appropriately formulated oral A09AC preparation.

Similarly, routine expression and disposal of breast milk (“pump and dump”) is not pharmacologically justified as a general class recommendation.

No class-wide requirement exists to separate maternal dosing from breastfeeding by a particular interval. Such timing strategies would be unlikely to provide meaningful additional protection for substances whose principal action is intraluminal and whose systemic exposure is limited.

Routine laboratory monitoring of a healthy, term breastfed infant is not generally required solely because of maternal treatment with an A09AC preparation.

However, A09AC is a heterogeneous combination class, and this qualification is central to safe clinical interpretation. Breastfeeding compatibility should ultimately be confirmed from the complete composition of the specific medicinal product.

Particular attention should be paid to:

·        the identity and concentration of the acidifying component;

·        the source and type of digestive enzyme or enzyme mixture;

·        additional active ingredients not intrinsic to the A09AC concept;

·        excipients with clinically relevant properties;

·        maternal dose and duration of treatment;

·        maternal renal, metabolic, gastrointestinal, or allergic disease;

·        prematurity, neonatal illness, or unusual susceptibility of the breastfed infant.

Products containing additional pharmacologically active substances require separate lactation assessment of those substances. The favorable mechanistic profile of digestive enzymes cannot be used to infer the safety of unrelated ingredients present in the same formulation.

Likewise, accidental ingestion of concentrated acidifying material should not be evaluated using routine breastfeeding recommendations for therapeutic A09AC products. Significant maternal poisoning requires individual toxicological management, and lactation decisions should then reflect maternal clinical status, associated treatments, and any possibility of external chemical contamination.

Overall lactological assessment

Conclusion

A09AC enzyme and acid preparations, combinations, are generally compatible with breastfeeding when used orally in appropriate therapeutic formulations and doses.

The available direct lactation evidence for the class is limited, and a universal quantitative relative infant dose cannot be established. Nevertheless, the pharmacological characteristics of these preparations provide substantial mechanistic reassurance: their intended action occurs predominantly within the gastrointestinal lumen, intact digestive enzymes are expected to undergo gastrointestinal degradation with minimal systemic availability, and acidifying components are subject to physiological buffering, dissociation, and metabolic or electrolyte regulation.

The major limitation of any class-wide assessment is formulation heterogeneity. A09AC should therefore be regarded as a pharmacological framework rather than as evidence that every product carrying this ATC designation has an identical lactation safety profile.

For routine clinical practice, appropriately used enzyme–acid combinations are unlikely to result in clinically important exposure of a breastfed infant. More detailed assessment should be performed at the level of the individual A09AC subclass, active ingredients, formulation, and patient circumstances whenever these factors could materially alter risk.